The Hypothesis
The male-specific longevity boost from acarbose isn't just about blunting systemic glucose. I propose it stems from a sex-dimorphic response to portal vein influxes of short-chain fatty acids (SCFAs)—mainly butyrate and propionate. These trigger hepatic AMPK phosphorylation far more efficiently in males, likely because hormonal environments dictate how G-protein-coupled receptors (GPR41/43) are expressed.
Mechanistic Reasoning
The ITP studies confirm acarbose blunts glucose, but that model doesn't explain why female mortality plateaus. I suspect the microbiome, which shifts toward Lactobacillus and Bifidobacteriaceae with treatment, acts as a secondary endocrine organ. Acarbose shunts undigested starch to the distal gut, spiking SCFA production. My hypothesis is that these SCFAs travel to the liver, binding to GPR41/43 on hepatocytes.
In male HET3 mice, testosterone likely upregulates these receptors or boosts their signaling to the AMPK-SIRT1 axis. This creates a "fasting-mimetic" liver state that doesn't rely on insulin. In females, estrogen might interfere with this GPR-AMPK pathway, leaving them insensitive to the SCFA-mediated longevity signal, even if their microbial shifts look identical to the males'.
The 'Inactivation' Variable
Research from Princeton shows that some gut microbes can inactivate acarbose, making the drug’s real-world bioavailability





























